Eur Heart J:心脏再同步治疗的心力衰竭患者心脏猝死风险的时间趋势

2019-11-24 xing.T MedSci原创

由此可见,随着时间的推移,CRT治疗的心力衰竭人群心脏猝死发生率逐渐降低。CRT-D与CRT-P接受者之间的差异明显缩小。

虽然来自随机试验的数据表明心力衰竭患者中心脏猝死(SCD)的发生率下降,但尚未评估心脏再同步治疗(CRT)患者中这种趋势的程度。近日,心血管领域权威杂志Eur Heart J上发表了一篇研究文章,研究人员评估了过去20年来CRT接受者中SCD发生率的变化以及相关因素。 

研究人员从数据库成立到2018年4月30日检索了纳入CRT患者(有或没有除颤器)且提供特定死亡原因数据的观察性和随机性研究。心脏猝死是该研究的主要终点。对于每项研究,均计算了每1000个患者每年的SCD发生率。随后构建趋势线图以评估SCD发生率随时间的变化,然后根据设备类型、患者特征和药物治疗对其进行进一步分析。

该分析共纳入了53项研究,包含22351例患者,随访60879人次每年,共585例SCD。自2000年代初以来,随机和观察性研究中SCD的发生率逐渐下降,下降了四倍多。 SCD的下降速度比全因死亡率的下降速度更大,因此,多年来由于SCD导致死亡的比例下降了。与接受CRT除颤器(CRT-D)的患者相比,CRT起搏器(CRT-P)患者中SCD的绝对下降幅度更为显著,CRT-P和CRT-D患者之间的SCD发生率差异在很大程度上有所降低。随着年龄的增长、β受体阻滞剂的使用和左心室射血分数的增加,SCD发生率逐步增加,反之,随QRS持续时间和抗心律失常药物的使用而逐渐减少。

由此可见,随着时间的推移,CRT治疗的心力衰竭人群心脏猝死发生率逐渐降低。CRT-D与CRT-P接受者之间的差异明显缩小。 

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1951608, encodeId=a16119516087a, content=<a href='/topic/show?id=53a5595e1dc' target=_blank style='color:#2F92EE;'>#时间趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59571, encryptionId=53a5595e1dc, topicName=时间趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed Dec 11 20:42:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357308, encodeId=a85a135e30889, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Nov 26 00:42:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542112, encodeId=1a0615421120f, content=<a href='/topic/show?id=78d751435bb' target=_blank style='color:#2F92EE;'>#心脏再同步治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51435, encryptionId=78d751435bb, topicName=心脏再同步治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a8d13352992, createdName=124984e7m87暂无昵称, createdTime=Tue Nov 26 00:42:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542927, encodeId=eb5b154292e67, content=<a href='/topic/show?id=a93d681e1ff' target=_blank style='color:#2F92EE;'>#猝死风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68171, encryptionId=a93d681e1ff, topicName=猝死风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=921913505832, createdName=ms3323097325231039, createdTime=Tue Nov 26 00:42:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563175, encodeId=b4cf15631e512, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Nov 26 00:42:00 CST 2019, time=2019-11-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1951608, encodeId=a16119516087a, content=<a href='/topic/show?id=53a5595e1dc' target=_blank style='color:#2F92EE;'>#时间趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59571, encryptionId=53a5595e1dc, topicName=时间趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed Dec 11 20:42:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357308, encodeId=a85a135e30889, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Nov 26 00:42:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542112, encodeId=1a0615421120f, content=<a href='/topic/show?id=78d751435bb' target=_blank style='color:#2F92EE;'>#心脏再同步治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51435, encryptionId=78d751435bb, topicName=心脏再同步治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a8d13352992, createdName=124984e7m87暂无昵称, createdTime=Tue Nov 26 00:42:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542927, encodeId=eb5b154292e67, content=<a href='/topic/show?id=a93d681e1ff' target=_blank style='color:#2F92EE;'>#猝死风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68171, encryptionId=a93d681e1ff, topicName=猝死风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=921913505832, createdName=ms3323097325231039, createdTime=Tue Nov 26 00:42:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563175, encodeId=b4cf15631e512, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Nov 26 00:42:00 CST 2019, time=2019-11-26, status=1, ipAttribution=)]
    2019-11-26 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1951608, encodeId=a16119516087a, content=<a href='/topic/show?id=53a5595e1dc' target=_blank style='color:#2F92EE;'>#时间趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59571, encryptionId=53a5595e1dc, topicName=时间趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed Dec 11 20:42:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357308, encodeId=a85a135e30889, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Nov 26 00:42:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542112, encodeId=1a0615421120f, content=<a href='/topic/show?id=78d751435bb' target=_blank style='color:#2F92EE;'>#心脏再同步治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51435, encryptionId=78d751435bb, topicName=心脏再同步治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a8d13352992, createdName=124984e7m87暂无昵称, createdTime=Tue Nov 26 00:42:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542927, encodeId=eb5b154292e67, content=<a href='/topic/show?id=a93d681e1ff' target=_blank style='color:#2F92EE;'>#猝死风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68171, encryptionId=a93d681e1ff, topicName=猝死风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=921913505832, createdName=ms3323097325231039, createdTime=Tue Nov 26 00:42:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563175, encodeId=b4cf15631e512, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Nov 26 00:42:00 CST 2019, time=2019-11-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1951608, encodeId=a16119516087a, content=<a href='/topic/show?id=53a5595e1dc' target=_blank style='color:#2F92EE;'>#时间趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59571, encryptionId=53a5595e1dc, topicName=时间趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed Dec 11 20:42:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357308, encodeId=a85a135e30889, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Nov 26 00:42:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542112, encodeId=1a0615421120f, content=<a href='/topic/show?id=78d751435bb' target=_blank style='color:#2F92EE;'>#心脏再同步治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51435, encryptionId=78d751435bb, topicName=心脏再同步治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a8d13352992, createdName=124984e7m87暂无昵称, createdTime=Tue Nov 26 00:42:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542927, encodeId=eb5b154292e67, content=<a href='/topic/show?id=a93d681e1ff' target=_blank style='color:#2F92EE;'>#猝死风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68171, encryptionId=a93d681e1ff, topicName=猝死风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=921913505832, createdName=ms3323097325231039, createdTime=Tue Nov 26 00:42:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563175, encodeId=b4cf15631e512, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Nov 26 00:42:00 CST 2019, time=2019-11-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1951608, encodeId=a16119516087a, content=<a href='/topic/show?id=53a5595e1dc' target=_blank style='color:#2F92EE;'>#时间趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59571, encryptionId=53a5595e1dc, topicName=时间趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed Dec 11 20:42:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357308, encodeId=a85a135e30889, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Nov 26 00:42:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542112, encodeId=1a0615421120f, content=<a href='/topic/show?id=78d751435bb' target=_blank style='color:#2F92EE;'>#心脏再同步治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51435, encryptionId=78d751435bb, topicName=心脏再同步治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a8d13352992, createdName=124984e7m87暂无昵称, createdTime=Tue Nov 26 00:42:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542927, encodeId=eb5b154292e67, content=<a href='/topic/show?id=a93d681e1ff' target=_blank style='color:#2F92EE;'>#猝死风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68171, encryptionId=a93d681e1ff, topicName=猝死风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=921913505832, createdName=ms3323097325231039, createdTime=Tue Nov 26 00:42:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563175, encodeId=b4cf15631e512, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Nov 26 00:42:00 CST 2019, time=2019-11-26, status=1, ipAttribution=)]
    2019-11-26 slcumt

相关资讯

Eur J Heart Fail:左心室射血分数对心脏再同步治疗长期疗效的影响

由此可见,在MADIT-CRT患者中,具有较高LVEF(>30%)的左束支传导阻滞患者表现出显著的逆向重塑时才能从CRT-D治疗中获得长期死亡率益处。

Eur Heart J:心脏再同步治疗患者的长期生存率和晚期心源性猝死

在这项首次描述CRT受者超长期结局的研究中,进行性心衰死亡仍然是CRT植入后存活5年患者的最常见死因。

病例分享:她的心衰病情何以迅速好转?巧合还是有据可循?

53岁女性,既往有高血压、糖尿病病史,无心脏疾病史,未发生过胸痛,来我院5个月前出现体力劳动时胸闷气喘,休息后可迅速缓解。之后接受中医药治疗4个月,症状逐渐加重,轻微活动即胸闷气喘并出现了夜间阵发性呼吸困难。

JAMA:心脏再同步治疗用于化疗性心肌病患者

研究认为,心脏再同步治疗可改善化疗性心肌病患者心脏功能,提高左室射血分数

Circulation:心脏再同步治疗的新指南建议

根据美国心脏病学会基金会(ACCF)、美国心脏协会(AHA)和心律学会(HRS)9月10日在《循环》杂志在线发表的一项报告,新版心律失常器械治疗指南对心脏再同步治疗(CRT)的应用进行了多处更新。 指南起草小组主席、乔治华盛顿大学电生理学系主任Cynthia M. Tracy博士指出,上版指南于2008年发布,新版指南“评估和阐明了目前最佳实践,并将继续反映技术的进步”。 新指南最显著的变化是

ESC 2013:CRT不能改善窄QRS波心衰患者预后

既往对心脏再同步治疗(CRT)的研究焦点多集中于QRS波时限>120 ms或>130 ms的患者,其结果显示此疗法可获得良好效果。但有部分QRS波时限正常的心力衰竭(心衰)患者,超声心动图(Echo)显示其存在明显的心脏机械不同步,这部分患者可否自CRT获益?现行指南仍将窄QRS波患者排除在CRT之外。刚刚结束的欧洲心脏病学会(ESC)年会上热线研究(Hot Line)专场公布的Ech